Fernando Argento

Fernando Argento

Auto-generated profile, based on publicly available information

Fernando Argento

Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2023 in Vaccine
Verified
Journal Article
Open access
ACAgustin Ciapponi
Agustin Ciapponi
MBMabel Berrueta
Mabel Berrueta
EPEdward P.K. Parker
Edward P.K. Parker
Ariel BardachAriel Bardach
Ariel Bardach
AMAgustina Mazzoni
Agustina Mazzoni
PBPierre Buekens
Pierre Buekens
Assessment of COVID-19 vaccines safety during pregnancy is urgently needed. We conducted a systematic review and meta-analysis to evaluate the safety of COVID-19 vaccines, including their components and technological platforms used in other vaccines during pregnancy and animal studies to complement direct evidence. We searched literature databases from its inception to September 2021 without language restriction, COVID-19 vaccine websites, and reference lists of other systematic reviews and the included studies. Pairs of reviewers independently selected, data extracted, and assessed the risk of bias of the studies. Discrepancies were resolved by consensus. (PROSPERO CRD42021234185). We retrieved 8,837 records from the literature search; 71 studies were included, involving 17,719,495 pregnant persons and 389 pregnant animals. Most studies (94%) were conducted in high-income countries, were cohort studies (51%), and 15% were classified as high risk of bias. We identified nine COVID-19 vaccine studies, seven involving 309,164 pregnant persons, mostly exposed to mRNA vaccines. Among non-COVID-19 vaccines, the most frequent exposures were AS03 and aluminum-based adjuvants. A meta-analysis of studies that adjusted for potential confounders showed no association with adverse outcomes, regardless of the vaccine or the trimester of vaccination. Neither the reported rates of adverse pregnancy outcomes nor reactogenicity exceeded expected background rates, which was the case for ASO3- or aluminum-adjuvanted non-COVID-19 vaccines in the proportion meta-analyses of uncontrolled studies/arms. The only exception was postpartum hemorrhage after COVID-19 vaccination (10.40%; 95% CI: 6.49-15.10%), reported by two studies; however, the comparison with non-exposed pregnant persons, available for one study, found non-statistically significant differences (adjusted OR 1.09; 95% CI 0.56-2.12). Animal studies showed consistent results with studies in pregnant persons. We found no safety concerns for currently administered COVID-19 vaccines during pregnancy. Additional experimental and real-world evidence could enhance vaccination coverage. Robust safety data for non-mRNA-based COVID-19 vaccines are still needed.

1 September 2021 in Vaccine
Verified
Journal Article
Closed access
ACAgustin Ciapponi
Agustin Ciapponi
Ariel BardachAriel Bardach
Ariel Bardach
AMAgustina Mazzoni
Agustina Mazzoni
TATomás Alconada
Tomás Alconada
SASteven A. Anderson
Steven A. Anderson
PBPierre Buekens
Pierre Buekens

15 December 2022 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
SMSebastian Garcia Marti
Sebastian Garcia Marti
LGLuz Gibbons
Luz Gibbons
SRSara Reidel
Sara Reidel
JSJuan Andrés Stupka
Juan Andrés Stupka
JDJuan Ignacio Degiuseppe
Juan Ignacio Degiuseppe
JGJorge A. Gomez
Jorge A. Gomez
Introduction Rotavirus (RV) is the most common cause of childhood diarrhea. Argentina introduced RV vaccination in the National Immunization Program in January 2015. This study evaluates the impact of RV vaccine implementation on the burden of acute diarrheal disease (ADD) and RV positive cases, and hospitalizations among children in Argentina. Methods A counterfactual time-series analysis was performed. Data on ADD (2013–2018) and RV diarrhea (2012–2018) cases in children aged < 5 years were collected from the National Healthcare Surveillance System (clinical and laboratory data). Data on hospital discharges following ADD and RV diarrhea (2011–2017) were retrieved from the Health Statistics and Information Office. All data were classified by the age groups < 1 year, < 2 years, 2–5 years. Vaccine impact was defined as the difference between the predicted time trend (simulated using 2012–2014 data) and the actual post-vaccination data (2015–2018). Results A significant reduction of 22.1% of notified ADD cases and 15.4% of hospital discharges following ADD among children < 2 years was observed in the 3 years after RV vaccine implementation. Data also showed a significant decline of 54.0% and 59.4% of notified RV cases in children < 2 and < 1 years, respectively, and a reduction of 39.3% and 40.8% in RV hospital discharges for the same age groups. Conclusion This study shows a significant reduction in notified ADD cases and RV cases and hospital discharges following ADD and RV cases in children < 2 years after RV vaccine introduction in Argentina in 2015. Graphical abstract

14 February 2025 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
JBJamile Ballivian
Jamile Ballivian
EPEdward P.K. Parker
Edward P.K. Parker
MBMabel Berrueta
Mabel Berrueta
ACAgustin Ciapponi
Agustin Ciapponi
FAFernando Argento
Fernando Argento
PBPierre Buekens
Pierre Buekens
Background: The COVID-19 pandemic induced the rapid deployment of novel vaccines with pregnant persons identified as an at-risk population due to their increased risk of severe outcomes. Limited data on the immunogenicity of COVID-19 vaccines in pregnant persons were available at the time of implementation. To address this data gap, we developed a living systematic review summarizing emerging evidence on vaccine immunogenicity in pregnancy. Methods: Following Cochrane, World Health Organization, and Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines, we included studies on COVID-19 vaccines during pregnancy. We carried out comprehensive biweekly literature searches from March 2022 to October 2023, covering multiple databases. Study selection, data extraction and risk of bias assessment were conducted by pairs of authors independently. Immunogenicity outcomes, primarily post-vaccination neutralizing or binding antibody concentrations, were analyzed descriptively. Post-vaccination antibody ratios in pregnant versus nonpregnant individuals were calculated for the subset of studies that included nonpregnant comparators. Results: By October 2023, our review encompassed 62 studies predominantly analyzing maternal sera (87%), with limited investigation regarding cord, neonatal and infant sera. Most studies investigated mRNA vaccines (97%) and focused on primary vaccination (82%), with some investigating booster doses (15%). Immunogenicity end points included spike-specific IgG (84%) and neutralizing antibodies (24%), with limited data on T-cell responses (3%). Antibodies were detectable after primary vaccination in most pregnant individuals, with similar or modestly attenuated concentrations compared to nonpregnant individuals (ratios > 0.7 for 5/6 estimates of spike-specific IgG), albeit with modest differences in antibody quality and kinetics. Long-term antibody-waning trajectories were similar between pregnant and nonpregnant individuals for up to 8 months after vaccination. Conclusions: mRNA COVID-19 vaccines induce a robust antibody response during pregnancy comparable (or modestly attenuated) relative to nonpregnant individuals. Immunogenicity data on non-mRNA vaccines are notably underrepresented in the existing literature.

1 January 2022 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
ACAgustin Ciapponi
Agustin Ciapponi
MBMabel Berrueta
Mabel Berrueta
Ariel BardachAriel Bardach
Ariel Bardach
AMAgustina Mazzoni
Agustina Mazzoni
SASteven A. Anderson
Steven A. Anderson
SZSabra Zaraa
Sabra Zaraa
Background: Assessment of COVID-19 vaccine safety during pregnancy is urgently needed to inform the public, advisory committees, and policymakers. Methods: We conducted a systematic review and meta-analysis to evaluate the safety of COVID-19 vaccines, including their components and technological platforms used in other vaccines during pregnancy. We searched literature databases from inception to September 2021 without language restriction, COVID-19 vaccine pregnancy websites, and reference lists of systematic reviews and the included studies. Pairs of reviewers independently selected studies through COVIDENCE and performed the data extraction and risk of bias assessment. Discrepancies were resolved by consensus. The study is registered in PROSPERO (CRD42021234185). Findings: We retrieved 8,837 records from the search strategy; 71 studies (61 clinical and 10 non-clinical studies, involving 17,719,495 pregnant persons and 389 pregnant animals, respectively) were included. Most studies (94%) were conducted in high-income countries and were cohort studies (51%). Less than 15% of studies were classified as high risk of bias. We identified nine COVID-19 vaccine studies, two preclinical studies, and seven involving 309,164 pregnant persons, mostly exposed to mRNA vaccines. Among non-COVID-19 vaccines, the most frequent exposures were to the AS03 adjuvant (23 studies) and aluminum-based adjuvants (31 clinical and five preclinical studies).A meta-analysis of the studies that adjusted for potential confounders and compared exposure to maternal COVID-19 vaccines or adjuvanted non-COVID-19 vaccines with no exposure showed no association with adverse outcomes, regardless of the vaccine or the trimester of vaccination. Proportional meta-analyses of uncontrolled studies or arms assessing pregnancy and safety outcomes of COVID-19 vaccines or adjuvanted non-COVID-19 vaccines (with AS03 or aluminum) estimated the ranges for each of the following outcomes: hypertensive disorders 2·37-3·98%; antenatal bleeding 0·37-0·44%; gestational diabetes mellitus 2·63-7·74%; spontaneous abortion/miscarriage 4·97-11·98%; stillbirth 0·06-0·20%; fetal death 0·82-1·36%; fetal growth restriction 0·49-0·89%; preterm birth 5·52-5·61%; low birth weight 3·73-6·84%; small for gestational age 6·84-11·98%; congenital malformations 2·32-4·97%; neonatal infections 3·24-7·23%; neonatal encephalopathy 0·23%; newborn respiratory distress syndrome 1·23-1·82%; and neonatal death 0·07-0·43%. Medically attended adverse events (33·9%) and serious adverse events (12·31%) were only available for aluminum-based adjuvant exposure. Neither pregnancy outcomes nor reactogenicity exceeded the expected rates. The only exception was postpartum hemorrhage after COVID-19 vaccination (10·40%; 95% CI: 6·49-15·10%), reported by two studies; however, the comparison with non-exposed pregnant persons in one study found non-statistically significant differences (adjusted OR 1·09; CI 95% 0·56 to 2·12). Interpretation: We found no safety concerns for currently administered COVID-19 vaccines during pregnancy. Further experimental and real-world evidence should expand these findings that reinforce current recommendations about vaccinating pregnant persons with approved COVID-19 vaccines. Robust safety data for non-mRNA-based COVID-19 vaccines are urgently needed. Funding: Bill & Melinda Gates Foundation Declaration of Interest: The authors have declared that no competing interests exist.

6 June 2021 in medRxiv
Verified
Preprint
Open access
PDF file
ACAgustin Ciapponi
Agustin Ciapponi
Ariel BardachAriel Bardach
Ariel Bardach
AMAgustina Mazzoni
Agustina Mazzoni
TATomás Alconada
Tomás Alconada
SASteven Anderson
Steven Anderson
PBPierre Buekens
Pierre Buekens
Background Pregnant women with COVID-19 are at an increased risk of severe COVID-19 illness as well as adverse pregnancy and birth outcomes. Many countries are vaccinating or considering vaccinating pregnant women with limited available data about the safety of this strategy. Early identification of safety concerns of COVID-19 vaccines, including their components, or their technological platforms is therefore urgently needed. Methods We conducted a rapid systematic review, as the first phase of an ongoing full systematic review, to evaluate the safety of COVID-19 vaccines in pregnant women, including their components, and their technological platforms (whole virus, protein, viral vector or nucleic acid) used in other vaccines, following the Cochrane methods and the PRISMA statement for reporting (PROSPERO-CRD42021234185). We searched literature databases, COVID-19 and pregnancy registries from inception February 2021 without time or language restriction and explored the reference lists of relevant systematic reviews retrieved. We selected studies of any methodological design that included at least 50 pregnant women or pregnant animals exposed to the vaccines that were selected for review by the COVAX MIWG in August 2020 or their components or platforms included in the COVID-19 vaccines, and evaluated adverse events during pregnancy and the neonatal period. Pairs of reviewers independently selected studies through the COVIDENCE web software and performed the data extraction through a previously piloted online extraction form. Discrepancies were resolved by consensus. Results We identified 6768 records, 256 potentially eligible studies were assessed by full-text, and 37 clinical and non-clinical studies (38 reports, involving 2,397,715 pregnant women and 56 pregnant animals) and 12 pregnancy registries were included. Most studies (89%) were conducted in high-income countries. The most frequent study design was cohort studies (n=21), followed by surveillance studies, randomized controlled trials, and registry analyses. Most studies (76%) allowed comparisons between vaccinated and unvaccinated pregnant women (n=25) or animals (n=3) and reported exposures during the three trimesters of pregnancy. The most frequent exposure was to AS03 adjuvant in the context of A/H1N1 pandemic influenza vaccines (n=24), followed by aluminum-based adjuvants (n=11). Aluminum phosphate was used in Respiratory Syncytial Virus Fusion candidate vaccines (n=3) and Tdap vaccines (n=3). Different aluminum-based adjuvants were used in hepatitis vaccines. The replication-deficient simian adenovirus ChAdOx1 was used for a Rift Valley fever vaccine. Only one study reported exposure to messenger RNA (mRNA) COVID-19 vaccines that also used lipid nanoparticles. Except for one preliminary report about A/H1N1 influenza vaccination (adjuvant AS03) - corrected by the authors in a more thorough analysis, all studies concluded that there were no safety concerns. Conclusion This rapid review found no evidence of pregnancy-associated safety concerns of COVID-19 vaccines that were selected for review by the COVAX MIWG or of their components or platforms when used in other vaccines. However, the need for further data on several vaccine platforms and components is warranted given their novelty. Our findings support current WHO guidelines recommending that pregnant women may consider receiving COVID-19 vaccines, particularly if they are at high risk of exposure or have comorbidities that enhance the risk of severe disease.